Frontier Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Frontier Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-195,959	Closed	-$14.7M	–	278
2022 Q2	$14.7M	Buy	195,959 +80,062	+69%	+$3.56M	0.17%	175
2022 Q1	$3.11M	Sell	115,897 -238,110	-67%	-$8M	0.03%	256
2021 Q4	$16.9M	Buy	354,007 +139,249	+65%	+$6.23M	0.13%	189
2021 Q3	$14.3M	Sell	214,758 -57,076	-21%	-$4.07M	0.11%	197
2021 Q2	$21.2M	Buy	271,834 +268,135	+7,249%	+$19.8M	0.16%	180
2021 Q1	$350K	Sell	3,699 -128,733	-97%	-$15.3M	﹤0.01%	275
2020 Q4	$16.1M	Buy	132,432 +2,964	+2%	+$325K	0.12%	202
2020 Q3	$11.3M	Buy	+129,468	New	+$9.02M	0.1%	206

Frontier Capital Management's TPTX Position: Q3 2022 in Review

Frontier Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 195,959 shares — an estimated $14.7M sold.

Frontier Capital Management first reported a position in TPTX in Q3 2020 and held it in 8 quarters. The position peaked at $21.2M in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Frontier Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Frontier Capital Management sold 195,959 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $14.7M.
Frontier Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 8 quarters.
Frontier Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $21.2M in Q2 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Frontier Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.